Ensemble Orthopedics Announces 35th Implantation Of Minimally Invasive CMC Device To Be Showcased At 2021 ASSH Meeting

Ensemble Orthopedics Inc, a privately held company, today announced the 35th implantation of its interpositional CMC device for the treatment of carpometacarpal (CMC or thumb) osteoarthritis.

The company will showcase the Ensemble CMC™ at booth #526 during the 76th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on September 30-October 2 in San Francisco.

The surgery was performed on September 1, 2021 at Ocala Regional Medical Center in Ocala FL by Dr. Nirav Gupta who stated, “The beauty of the Ensemble CMC™ is its simplicity. By leaving surrounding soft tissue and bony structures intact, the procedure allows for decreased operative time. Most importantly, the patients I have implanted with this device demonstrate reduced pain levels and earlier return to function than other surgical treatment options I have used. This implant allows me to expand my practice to patients with moderate, isolated CMC osteoarthritis of the thumb in which symptoms persist despite non-operative management.”

The FDA-cleared Ensemble CMC™ is the first implant in a full product line of minimally invasive, interpositional joint replacement devices for the hand and wrist. “We are encouraged by the short-term clinical outcomes and the pattern of repeated use amongst our trained surgeons,” said William Ogilvie, Co-founder, President and CEO of Ensemble Orthopedics. “These results support the concept of using minimally invasive techniques for hand arthroplasty that provide patients a quicker return to normal function.”

The Ensemble CMC™ was designed to expand the treatment options for osteoarthritis of the carpometacarpal joint in a broader range of patients. The minimally invasive, simple surgical procedure inserts an implant through a small incision without disrupting the surrounding soft tissue structures that stabilize the joint. The device is manufactured from pyrocarbon, a strong, low-friction, biocompatible material which has been shown to provide an ideal surface for sliding contact with bone and cartilage.

Ensemble Orthopedics, a medical device company based in Austin TX, develops proprietary, interpositional implants designed to employ minimally invasive surgical techniques, thereby retaining stabilizing tendons and ligaments, for the treatment of arthritis in the hand and wrist.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version